Invest in DataBiologics

Introduction

DataBiologics is transforming regenerative medicine by providing the essential evidence that physicians and patients need to make informed treatment choices in a field currently lacking robust data. Regenerative medicine, involving treatments like platelet-rich plasma (PRP), shockwave therapy, and stem cells derived from patient fat or bone marrow, is an exciting but largely unregulated frontier. The lack of predictable outcomes and clinical evidence often makes it seem like the "Wild West."

Platform Overview

DataBiologics fills this gap with an automated software platform that enables private practitioners to collect, analyze, and share real-world evidence effectively. Unlike costly and complex research systems used in academic hospitals, DataBiologics' solution is designed for everyday clinics, empowering practitioners to validate the effectiveness of new therapies. This allows physicians to offer better care while also supporting patients in confidently investing in treatments not typically covered by insurance.

Company Traction

DataBiologics has experienced remarkable traction, now serving over 200 providers across the US and Canada, fueled entirely by organic growth and the influence of respected thought leaders in regenerative medicine. Our early adopters, many of whom are prominent figures in their specialties, have become our biggest advocates, sharing their success stories and driving interest within the physician community. This network effect has allowed us to grow rapidly without traditional marketing efforts, proving the effectiveness and value of our platform through real-world results and peer endorsements. The strong support from influential clinicians underscores our credibility and solidifies our leadership in the regenerative medicine space.

Growing Patient Demand

The growing demand for regenerative medicine is driven in large part by an aging population that is increasingly prioritizing health, mobility, and quality of life. Traditional treatments often fall short of addressing chronic conditions like osteoarthritis or sexual dysfunction without significant side effects or invasive procedures.

Patients today are seeking more personalized, natural, and less invasive healthcare solutions, and they are willing to invest directly in their wellbeing. This trend is evident in the rise of medical tourism, with individuals traveling abroad for treatments that may not yet be widely available or approved in their home countries. Cash-pay options like PRP and stem cell therapies offer exactly what many of these patients are looking for: a way to improve their health outcomes without the limitations imposed by insurance companies or down-time associated with more invasive standard of care.

This willingness to pay out-of-pocket reflects a broader shift towards consumer-driven healthcare, where patients are seeking control, value, and evidence that their investments in their health will truly pay off.

Physician Adoption of Regenerative Medicine

The healthcare landscape is changing, with a growing number of patients seeking natural, less invasive options for managing age-related conditions like osteoarthritis and chronic pain. Cash-pay treatments such as PRP and shockwave therapy provide an attractive solution, offering immediate revenue without the complexity of insurance or the pressures of declining reimbursement.

A simple weekend training course allows any licensed provider—from nurse practitioners to surgeons—to learn the procedure, which involves using a centrifuge and specialized kits to process and inject blood. The low cost and seamless integration into existing clinic setups make it an easy new service line for practices looking to meet patient demand.

Field Challenges - Misinformation and Lack of Evidence

Regenerative medicine is often compared to the "Wild West," and for good reason. Despite the exciting potential of biologic treatments like PRP, there is a disturbing lack of standardized evidence to support their use. 

Patients face a landscape full of flashy marketing claims, but without the clinical data to validate them, these treatments can feel like a gamble. Adding to the confusion is the sheer number of available devices, most of which have only achieved the minimum FDA approval necessary to be marketed. This inconsistency in device quality, processing methods, and practitioner expertise makes it incredibly difficult for patients to make informed decisions.

The cost disparities are also striking. Depending on the biologic used, patients can pay anywhere from $1500 for a single PRP injection to over $40k for a series of stem cell treatments. Without adequate, accessible evidence to show what actually works and why, these price tags can feel like little more than a gamble. Patients are effectively placing their trust in a treatment and provider without any assurance that it is backed by reliable clinical proof. 

DataBiologics Solution and Benefits

DataBiologics is bringing order and clarity to regenerative medicine with a standardized software platform that collects, analyzes, and shares real-world evidence on treatments like PRP and other emerging technologies. 

Our platform allows physicians to gather long-term patient outcome data in real time using an easy-to-use automated system, which helps them understand what works best for different patient profiles. By aggregating data across a network of clinics, DataBiologics provides a valuable tool for benchmarking, improving practice performance, and building patient trust.

Customer Growth and Platform Utilization

DataBiologics has gained incredible momentum by addressing a significant gap in regenerative medicine: the lack of trustworthy, evidence-backed outcomes data that empowers both physicians and patients. Since our launch, we have rapidly expanded our clinician network and accumulated unique patient data that is unavailable anywhere else in cash-pay regenerative medicine. 

Our growth is evident in our 620% year-over-year ARR increase from August 2023 to August 2024, fueled largely by early adopters who have driven word-of-mouth referrals. This surge in adoption has led to over 20,000 active patient cases, more than doubling enrollments in just 12 months.

Early Adopter Loyalty

Early adopters have not only been crucial in spreading awareness but have also demonstrated impressive loyalty, with 82% of early trial users converting to paying customers. This high conversion rate reflects the strong value they derive from our platform in terms of improving patient engagement, gathering evidence for better outcomes, and ultimately growing their practices. 

Furthermore, our paying customer retention rate stands at an impressive 92%, indicating that once clinicians integrate our platform, they see ongoing, sustainable benefits. This high retention is due to our consistent focus on providing user-driven features and insights that meet the everyday needs of busy healthcare providers. 

Together, the combination of rapid network expansion, strong conversion rates, and enduring loyalty demonstrates the measurable impact and value that DataBiologics delivers to the regenerative medicine community.

Academic Validation of an Emerging Field

DataBiologics has been at the forefront of regenerative medicine, staying ahead of the curve in an evolving field where adoption is rapidly accelerating. In the past four years, the field has gained credibility, with institutions like Mayo Clinic, Stanford, and Cleveland Clinic now formally recognizing its potential. While these academic leaders are just beginning to establish the necessary groundwork for mainstream adoption, DataBiologics is already leading with a wealth of real-world data unmatched in scope and scale.

Our Network is Ahead of the Curve

Our platform now manages over 20,000 active patient cases, collected by a growing nationwide network of clinicians. Unlike traditional, slow-moving research models limited to isolated trials, DataBiologics provides a real-time, comprehensive dataset that empowers clinical decision-making today. This evidence base not only guides our users but also sets a benchmark for institutions, helping them advance the field more efficiently.

What sets DataBiologics apart is our ability to benchmark and rank physicians and products across diverse, unaffiliated practices—something nearly impossible in siloed, insurance-based healthcare. 

Practitioners can compare their outcomes to national standards, identify leaders, and refine their methods based on peer insights. We are lightyears ahead in creating a standardized, transparent, and data-driven foundation for regenerative medicine, far surpassing what traditional systems can achieve.

Leading the Future with AI

DataBiologics is uniquely positioned to drive the future of regenerative medicine by harnessing AI through our expansive, clean, and standardized database. Our AI-powered roadmap streamlines and accelerates patient access to treatments that enhance healthspan—not just lifespan.

Humans in the Loop for Reliable Insights

Our strength lies in meticulously standardized real-world data combined with experienced experts—our "humans in the loop"—who provide essential context. This blend makes DataBiologics the most reliable and actionable resource in regenerative medicine, ensuring insights are grounded in both clinical realities and advanced data science.

Transforming Data Interactions

Our platform revolutionizes how physicians and patients interact with data. Using our fundamental database, our AI ecosystem powers diverse use cases, from medical education and compliance-focused marketing to advanced patient-provider matching. Our tools can generate patient education materials, medical education content, and peer-reviewed publications—all while adhering to FCC/FDA compliance, delivering tailored insights to every stakeholder.

Empowering Patients and Providers

We can use the power of AI to benchmark outcomes, rank providers, and create digital twin profiles, offering unprecedented insights to patients and clinicians alike. Patients can find the best-fit providers based on real-world data, while physicians gain access to best practices by learning from aggregated data across different clinics.

Democratizing Access to Knowledge

By democratizing access to vital data, DataBiologics makes it easier for patients to find the best options for their needs, and for providers to refine care continuously. Our holistic, AI-driven approach reduces costs, enhances efficiency, and expands access to high-quality regenerative treatments, paving the way for the future of medicine.

Founded by Physicians for Physicians

DataBiologics was founded to address a critical gap in regenerative medicine—a lack of credible, standardized data. The idea originated with our physician founders, who saw firsthand how the absence of reliable outcomes data was limiting the adoption and growth of regenerative treatments. Recognizing the need for a solution that could empower both clinicians and patients, they envisioned a platform that would collect, validate, and share real-world evidence in a streamlined way.

Leah Braddell: Visionary Leadership

Leah Braddell, CEO and Chief Technology Officer, brings over two decades of experience in healthcare, combining expertise in commercial leadership, biomedical engineering, and data science. Known for her unique experience and award-winning success with disruptive technologies like Intuitive's da Vinci surgical robotics system, Leah joined DataBiologics in late 2022. Her career spans roles in sales, marketing, custom analytics, and clinical adoption of new medical technologies. Leah is driven by a central question: why isn’t healthcare adopting evidence-driven innovation faster? Her solution is a platform that’s simple enough for any private practice to use but powerful enough to drive industry-wide change.

Luke Malanga: Driving Product Vision

Luke Malanga, COO and Chief Product Officer, is a tech-savvy entrepreneur and the son of the late co-founder Dr. Gerard Malanga MD, a renowned educator in the field. Luke complements Leah's deep expertise with his passion for using data to solve complex problems. His forward-thinking approach has been pivotal in developing DataBiologics’ product roadmap, ensuring each feature meets the needs of end users—physicians and patients. Luke's focus on user experience, scalability, and seamless AI integration has transformed the company’s vision into a functional and impactful platform.

The Ecosystem of Expertise

DataBiologics' growth and expansion are driven not just by its founders, but by an ecosystem of "humans in the loop"—a community of leading practitioners, data scientists, engineers, and regulatory experts. This collective expertise ensures that every aspect of data collection, algorithm development, and insight generation is contextualized, relevant, and actionable. The blend of human expertise and cutting-edge technology positions DataBiologics at the forefront of regenerative medicine, pushing the boundaries of what’s possible in healthcare.

Organic Growth through Physician Influencers

DataBiologics has grown organically, driven primarily by word-of-mouth within the physician community. Adoption of innovative solutions like regenerative medicine is often led by influential peers—doctors who use the platform, see the results, and share their successes. 

Our early adopters, who recognized the potential of regenerative treatments but were frustrated by the lack of credible evidence, have become our strongest advocates. Their success stories have formed the foundation of our growth, enabling us to expand rapidly without heavy marketing investments.

Expansion of Services to Industry and Researchers

The commitment of these early adopters has not only expanded our clinician network but also attracted interest from medical device companies and other research groups seeking to collaborate. 

These industry partners are eager to tap into the high volume of real-world patient feedback we’ve collected across numerous products and treatments. By leveraging the unique insights generated by our platform, medical device manufacturers can understand product efficacy in real-world settings, refine their devices, and foster collaboration with our physician network. 

Likewise, research groups are utilizing our data to accelerate studies, making DataBiologics a central hub for innovation and validation in the field. This expansion underscores the value of our comprehensive dataset and positions us as a key player in advancing regenerative medicine through cross-industry collaboration.

Platform Evolution - IMPACT and ACCESS

The evolution of DataBiologics has led to the development of two distinct products. Our IMPACT platform serves healthcare providers by tracking and analyzing practice data, contributing to our growing IMPACT registry database. 

The ACCESS platform offers HIPAA-compliant, anonymized data insights to medical device companies and researchers. Through our IMPACT and ACCESS products, we've created a new dynamic between device manufacturers and providers, facilitating collaboration and shared learning. Medical device companies can now gain real-world insights and connect directly with leading practitioners, creating a virtuous cycle of innovation, feedback, and product improvement.

Subscription Model

DataBiologics offers multi-tiered subscription models tailored to the diverse needs of healthcare providers and industry partners. The IMPACT plan includes Starter, Essentials, and Performance tiers ranging from $249 to $4,495 per year, offering scalability in data collection, patient management, and analytics. 

The ACCESS plan provides Basic, Standard, and Premium options, starting at $5,000 per year, providing data extracts, advanced analytics, professional services, and collaborative solutions. This approach ensures each user, whether a clinic or a medical device company, can choose the right level of engagement, enabling scalable growth and impactful collaboration.

Regulatory Market Factors Driving Urgency

The need for capturing Patient Reported Outcomes (PROs) is becoming increasingly urgent, driven by significant regulatory and market shifts. TEFCA regulations now enforce interoperability and seamless data sharing, pushing healthcare systems to make patient data more accessible for clinical decision-making. 

CMS is also introducing PRO requirements that will directly impact reimbursement structures, with clinicians in orthopedics required to report patient-reported outcomes to secure optimal payments by 2027. 

Additionally, the European Medicines Agency (EMA) mandates that manufacturers track real-world outcomes for regulatory compliance, emphasizing the need for robust data collection to support market access.

DataBiologics Positioned for Enabling Compliance and Care Improvement

These evolving requirements are creating demand for comprehensive, standardized data that both providers and manufacturers can effectively leverage. DataBiologics is uniquely positioned to meet this need, with our platform already focused on collecting and analyzing real-world outcomes data. As regulatory frameworks increasingly emphasize patient-reported metrics, the value of our comprehensive database continues to grow, allowing providers to stay compliant while improving patient care and demonstrating the effectiveness of their treatments.

Driving Future Demand and Market Leadership

The regulatory push for outcomes tracking not only positions DataBiologics as an immediate compliance solution but also accelerates future demand for our platform. Our commitment to real-world data collection, paired with a strong network of clinician users, places us as a pivotal player in an emerging and disruptive market. 

As stakeholders across the healthcare ecosystem—including providers, medical device companies, and regulators—recognize the necessity of high-quality, accessible patient data, DataBiologics is poised to lead this shift. By providing the infrastructure necessary to meet both current and evolving regulatory requirements, we are not merely keeping up with industry changes—we are shaping the future of a more transparent, data-driven approach to regenerative medicine.

Market Size

The market opportunity for DataBiologics is immense, and our go-to-market strategy is precisely crafted to capture the expanding demand in the regenerative medicine landscape. 

Our Total Addressable Market (TAM) is approximately $125 billion, encompassing the U.S. healthcare research and marketing spend, driven by an increasing interest in cash-based treatment options like regenerative therapies. 

From this broad market, we've identified our Serviceable Available Market (SAM) at $4.7 billion, which includes over 1 million healthcare providers who have the potential to integrate regenerative or other innovative and cash-based treatments into their practices. 

Within this framework, our Serviceable Obtainable Market (SOM) represents a $2.9 billion opportunity focused on 650,000 ideal clinicians. 

These ideal profile clinicians, operating across specialties like physical medicine and rehabilitation, sports medicine, pain management, orthopedic surgery, chiropractic/physical therapy, urology, and gynecology, are most likely already adopting regenerative and cash-based options or can be enabled to do so with low barrier to entry. 

These providers are perfectly positioned to benefit from the evidence-backed insights our platform and physician network provides. 

Targeted Go-to-Market Strategy

To accelerate our market penetration, we are implementing a high-powered Customer Relationship Management (CRM) system that is integral to our go-to-market strategy. Our CRM approach involves curated outbound mailing lists, strategic social media marketing, SEO optimization, and messaging tailored specifically to clinicians whose practice profiles match those of our current successful users.

By utilizing advanced segmentation and targeting techniques, our CRM groups practitioners with similar characteristics, challenges, and potential as our existing customers, ensuring a high conversion likelihood.

This personalized outreach, coupled with our proven word-of-mouth referrals, will help us expand efficiently and cost-effectively. Our goal is to drive rapid adoption among those who are most likely to see immediate value from our platform, thereby establishing a scalable foundation for deeper market penetration and long-term growth. By focusing on evidence-based, cash-pay solutions, we are not only transforming patient care but also helping providers grow their practice capabilities.

Scaling Marketing and Sales through Funding

Our ongoing fundraising efforts will further bolster our go-to-market strategy by supporting automation and scaling of our outbound marketing efforts. These funds will help us target potential IMPACT subscribers while expanding direct sales and support for our high-value ACCESS product. We also plan to enhance our presence at medical conferences to expand our brand positioning and relevance in the market.

Additionally, investments in our AI-powered product roadmap will accelerate development and support international expansion. While we expect to achieve profitability by early next year, we intend to pursue follow-on funding in a priced round to expedite growth and enhance our market position, ultimately setting up the company for a successful exit for our early shareholders. With this strategy, DataBiologics is positioned to lead in an emerging and disruptive market, creating value across the healthcare ecosystem.

Path to a Valuable Exit

DataBiologics is uniquely positioned for success, with a clear path to a highly valuable exit that aligns with precedents in healthcare data and patient experience. Comparable exits such as Flatiron Health, acquisition by Roche for $1.9 billion and Press Ganey's $4.2 billion sale to LGP and Ares Management highlight the high value of data-driven healthcare solutions. 

DataBiologics is creating a similar niche by aggregating and standardizing real-world treatment data, providing evidence-based insights that drive healthcare quality and decision-making. With an expanding clinician network and partnerships with industry leaders, we are positioned as an attractive acquisition target for healthcare giants, tech companies, or private equity firms aiming to transform healthcare delivery.

The Opportunity to Transform Healthcare

DataBiologics stands at the forefront of an emerging healthcare revolution, uniquely positioned to transform the future of regenerative medicine. With strong early traction, including a rapidly expanding clinician network, high conversion and retention rates, and significant ARR growth, we have proven the value and demand for our evidence-based platform. 

By establishing a firm foothold in a niche, high-growth field, we offer a distinct first-mover advantage in an industry ripe for disruption. Our strengths lie in our comprehensive, real-world data collection, AI-driven insights, and our ability to democratize access to high-quality treatments that extend and enhance healthspan. 

We invite investors to take an active role in this journey, contributing to the transformation of healthcare and helping us expand our impact globally. Join us in unlocking the full potential of regenerative medicine and shaping a more transparent, effective, and patient-centric future.